B. Benjamin

发表

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

A. Chugh, A. Ray, A. Patra, 2011, European journal of pharmacology.

Development of Lipid-Based Nanoparticles for Enhancing the Oral Bioavailability of Paclitaxel

T. Dutta, V. Lather, A. Ahuja, 2011, AAPS PharmSciTech.

Enhanced expression of recombinant proteins utilizing a modified baculovirus expression vector

P. Tiwari, Sudhir Sahdev, K. Saini, 2010, Molecular biotechnology.

Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard.

M. Ramesh, N. Srinivas, R. Mamidi, 2003, Biomedical chromatography : BMC.

Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome.

A. Ray, V. Tulasi, J. A. Davis, 2017, Bioorganic & medicinal chemistry letters.

Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model

J. A. Davis, V. Bansal, V. Khanna, 2012, Indian journal of pharmacology.

Hematological Effects of Non-Homogenous Ionizing Radiation Exposure in a Non-Human Primate Model

Ž. Vujašković, E. Draeger, J. Eley, 2019, Radiation Research.

The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors

N. Srinivas, D. Abhyankar, B. Benjamin, 2012, Arzneimittelforschung/Drug Research.

Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.

Sandeep Sharma, N. Dubey, N. Srinivas, 2012, Biomedical chromatography : BMC.